Pelthos Therapeutics Inc.
PTHS · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.89 | -0.01 | 0.99 | -0.08 |
| FCF Yield | -17.80% | -5.54% | -8.74% | -9.53% |
| EV / EBITDA | -5.27 | -3.19 | -5.24 | -4.79 |
| Quality | ||||
| ROIC | -14.60% | 77.11% | 108.36% | 345.66% |
| Gross Margin | 54.31% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.94 | 0.13 | 0.32 | 0.35 |
| Growth | ||||
| Revenue 3-Year CAGR | 1,949,121.69% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -3,312.48% | 29.26% | 5.69% | -276.74% |
| Safety | ||||
| Net Debt / EBITDA | 0.76 | -0.70 | -1.29 | -0.92 |
| Interest Coverage | -11.41 | -14.78 | -13.72 | -16.90 |
| Efficiency | ||||
| Inventory Turnover | 0.14 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 587.23 | 0.00 | 0.00 | 0.00 |